GAMMA Investing LLC Purchases 7,058 Shares of AbbVie Inc. $ABBV

Key Points

• GAMMA Investing increased its AbbVie stake by 10.4% in the third quarter, acquiring 7,058 shares and bringing its holdings to 75,060 shares valued at approximately $19.6 million. Institutional investors and hedge funds own 70.23% of AbbVie.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $276.64; several firms recently raised their targets to between $270 and $300.
• AbbVie beat quarterly earnings and revenue estimates, while declaring a quarterly dividend of $1.73 per share, yielding about 2.5%. However, its roughly 195% payout ratio raises concerns about dividend sustainability, and an executive recently sold 32,710 shares.

GAMMA Investing LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 10.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,060 shares of the company's stock after acquiring an additional 7,058 shares during the period. AbbVie makes up 0.6% of GAMMA Investing LLC's holdings, making the stock its 24th largest position. GAMMA Investing LLC's holdings in AbbVie were worth $19,635,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ABBV. Galvin Gaustad & Stein LLC raised its stake in shares of AbbVie by 0.7% during the third quarter. Galvin Gaustad & Stein LLC now owns 6,941 shares of the company's stock valued at $1,816,000 after purchasing an additional 46 shares in the last quarter. Grove Bank & Trust lifted its holdings in AbbVie by 0.7% in the third quarter. Grove Bank & Trust now owns 15,465 shares of the company's stock worth $4,045,000 after purchasing an additional 112 shares during the period. Factor Wealth Management LTD grew its position in AbbVie by 1.1% in the 3rd quarter. Factor Wealth Management LTD now owns 19,240 shares of the company's stock valued at $5,033,000 after buying an additional 207 shares in the last quarter. Conrad Siegel Investment Advisors Inc. bought a new position in AbbVie in the 3rd quarter valued at about $201,000. Finally, Farther Finance Advisors LLC increased its stake in AbbVie by 10.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 132,821 shares of the company's stock valued at $34,745,000 after buying an additional 12,862 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. Bank of America reissued a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Argus upped their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $276.64.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

AbbVie Stock Performance

AbbVie stock opened at $272.20 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $274.94. The firm has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.23 and a beta of 0.24. The company has a 50 day moving average price of $258.56 and a 200 day moving average price of $236.35.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie Inc. will post 14.01 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook.
• Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.